One of the first things you need to do to ensure scalability and sustainability of social determinants of health (SDOH) initiatives is to really understand your population, explained Susan Mani, MD, vice president of Clinical Transformation and Ambulatory Quality at LifeBridge Health.
One of the first things you need to do to ensure scalability and sustainability of social determinants of health initiatives is to really understand your population, explained Susan Mani, MD, vice president of Clinical Transformation and Ambulatory Quality at LifeBridge Health.
Transcript
What are best practices for ensuring scalability and sustainability of social determinants of health initiatives?
I think one of the first things you really want to do is to understand your populations. It’s very easy to have what I call a jello on the wall approach, which you can just throw a lot of different initiatives based on what you read in a recent article, based on what you head from your best friend or another health system, but if you don’t know your population or what your population needs from looking at the data, then it’s very easy to go down this rabbit hole and to be able to scale. You could have 25 programs and still not be able to get to the outcomes that you need. I think that takes a certain amount of rigor and really spending time being strategic before you immediately start to operationalize.
Once you do that, then you can really start to hone in on what are the specific resources that you need by looking at your programs on a daily basis. By looking at process metrics, we really can tell where is the intensity of touch really needed, who is the number of the team that we really need to make sure that we have scalability on. For some of our patients, we’re finding it for their clinical needs. We really want to make sure we have the capacity for our nurses. For others where it really has to do with psychosocial needs, we really want to make sure that our social workers and our community health workers have that type of capacity, and depending on our zip code, depending on which patient population we’re looking at, those will be very different. Based on that, then you can start to scale. Start with a small population. We do pilots all the time. Based on that, we look and process and outcome metrics very robustly for all of our pilots. After 90 days, if we really are not getting to where we need, then we have to step back and say is this program the right program? Do we just need to tweak operationally, or do we really have to think about something differently?
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa
March 11th 2024Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Read More